Veltuzumab
Showing 1 - 9 of 9
Non Hodgkin's Lymphoma, NHL, Aggressive NHL Trial in United States (Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab
Withdrawn
- Non Hodgkin's Lymphoma
- +3 more
- Veltuzumab and 90Y-Epratuzumab Tetraxetan
- +2 more
-
Newark, Delaware
- +6 more
Aug 12, 2021
NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell Trial in United States (veltuzumab)
Completed
- NHL
- +17 more
- veltuzumab
-
Savannah, Georgia
- +4 more
Aug 12, 2021
Non-Hodgkin's Lymphoma, Lymphoma, Diffuse, Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic Trial in Lille, Lyon, Leicester
Completed
- Non-Hodgkin's Lymphoma
- +2 more
- veltuzumab
-
Lille, Cedex, France
- +2 more
Aug 12, 2021
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune Trial in
Terminated
- Purpura, Thrombocytopenic, Idiopathic
- +2 more
- veltuzumab
-
Los Angeles, California
- +7 more
Aug 12, 2021
Non-Hodgkin's Lymphoma Trial in New York, Philadelphia, Houston (hA20-humanized anti-CD20 antibody)
Completed
- Non-Hodgkin's Lymphoma
- hA20-humanized anti-CD20 antibody
-
New York, New York
- +2 more
Aug 12, 2021
Follicular Lymphoma Trial in New York (90Y-epratuzumab tetraxetan, veltuzumab)
Terminated
- Follicular Lymphoma
- 90Y-epratuzumab tetraxetan
- veltuzumab
-
New York, New YorkWeill Cornell Medical College
Jan 26, 2018
Lymphoma Trial in Columbus (milatuzumab, veltuzumab, Correlative/Special Studies)
Completed
- Lymphoma
- milatuzumab
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Dec 8, 2016
Rheumatoid Arthritis Trial in Worldwide (Veltuzumab)
Terminated
- Rheumatoid Arthritis
- Veltuzumab
-
La Mesa, California
- +62 more
Mar 13, 2016
Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia Trial in United Kingdom (humanised mAb, veltuzumab, humanised mAb
Unknown status
- Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
- humanised monoclonal antibody, veltuzumab
- +2 more
-
Birmingham, United Kingdom
- +9 more
Jul 11, 2014